Europe generic drugs market was valued at $123.4 billion in 2024 and is projected to reach $201.9 billion by 2035, growing at a CAGR of 4.7% during the forecast period (2025-2035). The European generic drug market is increasingly shaped by stringent regulatory frameworks, high consumer expectations for safety and efficacy, and growing demand for cost-effective therapeutic solutions. Oversight by the European Medicines Agency (EMA) and compliance with Good Manufacturing Practices (GMP) ensure high-quality formulations and bioequivalence, fostering trust among patients and healthcare providers. Companies are focusing on innovation in complex generics, specialty dosage forms, and injectable formulations to meet evolving treatment needs, while promoting accessibility and affordability across diverse Western, Central, and Eastern European markets. Rising awareness of sustainable practices and environmentally responsible manufacturing further supports adoption and brand credibility.
Browse the full report description of “Europe Generic Drugs Market Size, Share & Trends Analysis Report, By Application (Cancer, CVD, Musculoskeletal Diseases, Infectious Diseases, Neurology, Diabetes, and Others), By Route of Administration (Oral, Topical, Injectable, and Inhaler), Forecast Period (2025-2035)” of https://www.omrglobal.com/industry-reports/europe-generic-drugs-market
Germany Prescription Drug Market Revenue Growth and Segment Share (2018–2023)
According to the Germany Trade & Invest, Between 2018 and 2023, Germany’s prescription drugs segment experienced an annual revenue growth of nearly 6.0%, reaching around €65.3 billion ($70.6 billion) in 2023, with prescription-only medicines making up almost 90.0% of total sales, according to Germany Trade & Invest. This data highlights Germany’s significant contribution to Europe’s pharmaceutical market and underscores two key trends: the ageing population and the increasing prevalence of chronic and long-term diseases. Both factors are driving consistent demand for cost-effective, safe, and convenient therapies, particularly injectable treatments, including generic small-molecule formulations. The robust growth in Germany’s prescription segment reflects broader European market dynamics, where healthcare systems increasingly rely on generics to manage rising treatment costs, expand patient access, and address the growing burden of chronic diseases.
Innovation Leaders Transforming the European Generic Drug Market
The key players in the European generic drug market include Hikma Pharmaceuticals PLC, Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., among others. Companies operating in the European generic drug market are driving innovation through advanced manufacturing processes, bioequivalence-focused formulation development, and improved quality and stability profiles. These efforts support cost-effective drug production, supply reliability, and adherence to stringent regulatory standards set by the European Medicines Agency, while addressing rising demand for affordable therapies across chronic and acute disease segments.
Market Coverage
Key questions addressed by the report.
European Generic Drug Market Report Segment
By Route of Administration
By Application
European Generic Drug Market Report Segment by Region
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/europe-generic-drugs-market